Determining the Value of Two Biologic Drugs for Chronic Inflammatory Skin Diseases: Results of a Multi-Criteria Decision Analysis.
Néboa ZozayaLucía Martínez-GaldeanoBleric AlcaláJose Carlos Armario-HitaConcepción CarmonaY José Manuel CarrascosaPedro HerranzMaría Jesús LamasMarta Trapero-BertranÁlvaro Hidalgo-VegaPublished in: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (2018)
Under this methodology, and assuming similar economic costs per patient for both treatments, the results indicated that the overall value estimated of dupilumab for severe atopic dermatitis was similar to, or slightly higher than, that of secukinumab for moderate to severe plaque psoriasis.